

In The Claims:

The claims are amended as follows:

1-49. **(Cancelled)**

50. **(Previously Presented)** A method of determining a treatment regimen for a subject, comprising:

selecting said subject on the basis of a diagnosis of congestive heart failure, acute coronary syndrome or acute myocardial infarction;

performing an assay to specifically detect a natriuretic peptide in a sample obtained from said subject, wherein said natriuretic peptide is BNP₇₇₋₁₀₈; and

determining a treatment regimen based in part on the presence or amount of said natriuretic peptide, wherein said regimen includes one or more inhibitors of prolyl-specific DPP.

51. **(Previously Presented)** A method according to claim 50, wherein the inhibitor(s) of prolyl-specific DPP comprise a dipeptide analogue comprising an aza, azetadine, boronate, hydroxylamine, or phosphonate moiety.

52. **(Previously Presented)** A method according to claim 50, wherein the inhibitor(s) of prolyl-specific DPP comprise an antibody or fragment thereof.

53. **(Previously Presented)** A method according to claim 50, wherein said regimen further comprises one or more additional molecules selected from the group consisting of inhibitors of neutral endopeptidase and natriuretic peptides.

54. **(Previously Presented)** The method of claim 50, wherein said performing step comprises:

forming a complex between said natriuretic peptide and at least one antibody, wherein said antibody comprises a detectable label; and

detecting said complex.